The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
Conditions
Chronic Myelomonocytic Leukemia
Conditions: official terms
Leukemia - Leukemia, Myelomonocytic, Acute - Leukemia, Myelomonocytic, Chronic
Conditions: Keywords
To evaluate the phosphate and tension homolog deleted on chromosome ten (PTEN) protein level in leukemia cells from patients with CMML., To identify the PTEN genetic defect in patients with deficient PTEN protein levels., To evaluate the role of PTEN deregulation in CMML pathogenesis.
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case Control, Time Perspective: Prospective
Overall Status
Recruiting
Summary
The purpose of this study is to evaluate the level of a specific protein (PTEN) in the cancer cells of chronic myelomonocytic leukemia (CMML) patients. This protein might be involved in the transformation from normal blood cells to leukemia cells. The PTEN protein has not been investigated in CMML specifically but it has been discovered in closely related cancers. If this study demonstrates an abnormality in this protein, future testing will be designed to evaluate the genetic abnormality that resulted in lack of the normal presence of this protein. The goal is that the results of this study will help to develop new drugs and strategies to treat the future patients with CMML by understanding the abnormality of the disease at the cellular and molecular levels. The results of this study can also be utilized by future studies to develop individualized treatment to patients who have abnormal levels of this protein.
Criteria for eligibility
Healthy Volunteers: Accepts Healthy Volunteers
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Subject must be at least 18 years or older.

- Subject must sign informed consent.

- For study population only, the subject must have a CMML diagnosis based on the WHO 2009 criteria.

- For control population only, the subject must be deemed healthy with no hematologic disorders.
Location
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Status: Recruiting
Contact: Suzy Hall - Hallsusanf@uams.edu
Start Date
November 2009
Sponsors
University of Arkansas
Source
University of Arkansas
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page